Michael Khan
Algemeen Directeur bij Argonaute RNA Ltd.
Profiel
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Actieve functies van Michael Khan
| Bedrijven | Functie | Begin |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Algemeen Directeur | 01-01-2021 |
Eerdere bekende functies van Michael Khan
| Bedrijven | Functie | Einde |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Hoofd Techniek/Wetenschap/O&O | 17-06-2016 |
| University of Warwick | Corporate Officer/Principal | - |
Opleiding van Michael Khan
| University College London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Bedrijven in privébezit | 3 |
|---|---|
| Diabetes UK | |
| HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |